Development of next-generation adoptive immunotherapy using cytotoxic T-lymphocyte(CTL) expressing chimeric antigen-receptor(CAR)

DOI Web Site
  • Nakagawa Takeshi
    Laboratory of Biotechnology and Therapeutics, Graduate School of Pharmaceutical Sciences, Osaka University
  • Okada Naoki
    Laboratory of Biotechnology and Therapeutics, Graduate School of Pharmaceutical Sciences, Osaka University
  • Nakagawa Shinsaku
    Laboratory of Biotechnology and Therapeutics, Graduate School of Pharmaceutical Sciences, Osaka University

Bibliographic Information

Other Title
  • キメラ抗原受容体 （CAR） 発現細胞傷害性T細胞 (CTL) を用いた次世代養子免疫療法の開発
  • キメラ コウゲン ジュヨウタイ(CAR)ハツゲン サイボウ ショウガイセイ Tサイボウ(CTL)オ モチイタ ジセダイ ヨウシ メンエキ リョウホウ ノ カイハツ

Search this article

Abstract

Adoptive immunotherapy, relying on the transfer of tumor-specific cytotoxic T-lymphocytes (CTL) differentiated from CD8+ T cells of cancer patient, is autologous cell therapy attempting tumor regression and suppression of metastasis and recurrence. However, it is difficult to induce sufficient number of tumor-specific CTLs from most patients who are in immunosuppression. As a way out, development of the technique to create CTLs expressing chimeric antigen-receptor (CAR) is pushed forward. CAR comprises an extracellular target molecule recognition domain fused to a transmembrane domain and cytoplasmic signal transduction domain capable of modifying CTL function. Herein, we review trend of the CAR study and our next-generation adoptive immunotherapy using tumor vessel-specific CAR-expressing CTL.

Journal

  • Drug Delivery System

    Drug Delivery System 28 (1), 35-44, 2013

    THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

Keywords

Details 詳細情報について

Report a problem

Back to top